Saraff V, et al. - Experts undertook a comparative analysis of the efficacy and treatment costs of zoledronate and pamidronate in paediatric osteoporosis. It was discovered that zoledronate was a significantly cheaper alternative to pamidronate with comparable efficacy. This, in turn, led to considerable annual savings for healthcare providers. Additionally, it served as a more convenient option for patients due to fewer hospital visits.